UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JUNE 10, 2002 ANTIGENICS INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 000-29089 06-1562417 (STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NO.) INCORPORATION OR ORGANIZATION) 630 FIFTH STREET, SUITE 2100 NEW YORK, NEW YORK 10111 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES AND ZIP CODE) (212) 332-4774 (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE) ITEM 5. OTHER EVENTS. Samuel D. Waksal, Ph.D. resigned from the Board of Directors of the Registrant effective June 10, 2002. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANTIGENICS INC. Date: June 10, 2002 By: /s/ Garo H. Armen, Ph.D. ----------------------------------------- Garo H. Armen, Ph.D. Chairman and Chief Executive Officer 3